|
|
 | | | |
- close
- close
- close
- close
Generic drugs (small molecule) |
Forbes
7 hrs ago
Comment
It is a testament to how spoiled we have become by mainstream animated features that a film as visually arresting as Epic would be considered remotely run-of-the-mill. Chris Wedge's well-paced adventure saga is filled with lush imagery and rich...
FiercePharma
May 22
Comment
Generic competition, sales woes and R&D disappointments have put revenue on the decline and Merck ($MRK) in hot water, with the pharma giant earlier this month promising to buy back as much as $15 billion in shares. And yesterday, the company...
Forbes
May 20
Comment
The reasons that Actavis is willing to pay $8.5 billion, including debt, for Warner-Chilcott are fairly straightforward. By doing so, the generic drugmaker limits its exposure to the end of the patent cliff. Compared to the past few years, there...
StreetInsider.com
May 17
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Mylan+%28MYL%29+Launches+Generic+Tricor+Tabs+%28ABBV%29/8349783.html for the full story.
Reuters
May 16
Comment
Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
StreetInsider.com
May 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Mylan+%28MYL%29++Unit+Launches+Generic+Zomig+Tabs/8341139.html for the full story.
FiercePharma
May 15
Comment
How much is a generic drug worth to a payer? More than £350 million, for the U.K.'s National Health Service anyway. That's how much it saved during the first 12 months after Pfizer's Lipitor went off patent, the generic industry's trade...
The Hindu Business Line
May 15
Comment
Glenmark Pharmaceuticals Ltd today said that its subsidiary has received approval from the US health regulator to sell generic versions of AstraZeneca’s Zomig and Zomig ZMT tablets, a migraine dru...
Reuters
May 14
Comment
Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday.
The Hindu Business Line
May 14
Comment
Fourth quarter profit surges 66% to Rs 571 cr; to pay 300% final
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
